Expanding National Clinical Outcome Assessment Capacity with Train(e)d
To improve diagnosis, monitor disease progression, and evaluate treatment response, NMD4C’s Outcome Measures and Natural History (OMNH) group is building a national framework for outcome measure development and infrastructure for natural history studies, integrating patient-reported outcome measures, and expand diagnostic imaging capacity.
This work will support clinical trials, real-world evidence generation, and improved care for individuals living with NMDs.
As knowledge gaps in outcome measures assessments have become evident, MDC together with the NMD4C have developed Train(e)d, an on-demand e-learning platform designed to address gaps in evaluator training and improve the consistency of clinical assessments across Canada.
This platform is a part of NMD4C’s goal of developing resources that aim to harmonize outcome measures and promote accessible, sustainable, and validated training, thus increasing clinical capacity on a national level.
Enrollment keys are required to access our course modules. These will be provided by email within the next business day after registering.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.